In particular, somatic mutations in epidermal growth factor receptor (EGFR) are important parameters for determining the treatment response to EGFR tyrosine kinase inhibitors (EGFR-TKIs) in NSCLC [3,4]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.